| Literature DB >> 34558232 |
Di Wu1, Zongyi Wang1, Jun Li1, Yan Song2, Manuel Everardo Mondragon Perez1, Zixuan Wang1, Xia Cao1, Changliang Cao1, Sushila Maharjan1, Kenneth C Anderson2, Dharminder Chauhan2, Yu Shrike Zhang1.
Abstract
Multiple myeloma (MM) is a malignancy of plasma cells accounting for ≈12% of hematological malignancies. In this study, the fabrication of a high-content in vitro MM model using a coaxial extrusion bioprinting method is reported, allowing formation of a human bone marrow-like microenvironment featuring an outer mineral-containing sheath and the inner soft hydrogel-based core. MM cells are mono-cultured or co-cultured with HS5 stromal cells that can release interleukin-6 (IL-6), where the cells show superior behaviors and responses to bortezomib in 3D models than in the planar cultures. Tocilizumab, a recombinant humanized anti-IL-6 receptor (IL-6R), is investigated for its efficacy to enhance the chemosensitivity of bortezomib on MM cells cultured in the 3D model by inhibiting IL-6R. More excitingly, in a proof-of-concept demonstration, it is revealed that patient-derived MM cells can be maintained in 3D-bioprinted microenvironment with decent viability for up to 7 days evaluated, whereas they completely die off in planar culture as soon as 5 days. In conclusion, a 3D-bioprinted MM model is fabricated to emulate some characteristics of the human bone marrow to promote growth and proliferation of the encapsulated MM cells, providing new insights for MM modeling, drug development, and personalized therapy in the future.Entities:
Keywords: bioprinting; bortezomib; coaxial extrusion; multiple myeloma; tocilizumab
Mesh:
Substances:
Year: 2021 PMID: 34558232 PMCID: PMC8940744 DOI: 10.1002/adhm.202100884
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 11.092